ENLIVEN THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 1.08 million shares for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-10.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2023-02-10
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-12-31 was 34.61K shares, a 15.13% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-09-30 was 253.08K shares, a 329.66% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-06-30 was 756.87K shares, a 1126.13% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-03-31 was 30.65K shares, a 85.13% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 1.08M shares, a 201.28% increase from fiscal 2021.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 356.88K shares, a 15.17% decline from fiscal 2020.
- ENLIVEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2020 was 420.68K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2022-12-31 | 34.61K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | 287.69K shares derived: sum of 2 quarters · filed 2023-02-10 | 1.04M shares derived: sum of 3 quarters · filed 2023-02-10 | 1.08M shares 10-K · filed 2023-02-10 |
| 2022-09-30 | 253.08K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | 1.01M shares derived: sum of 2 quarters · filed 2022-10-25 | 1.04M shares 10-Q · filed 2022-10-25 | 1.07M shares derived: sum of 4 quarters · filed 2022-10-25 |
| 2022-06-30 | 756.87K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | 787.52K shares 10-Q · filed 2022-08-03 | 817.58K shares derived: sum of 3 quarters · filed 2022-08-03 | 876.48K shares derived: sum of 4 quarters · filed 2022-08-03 |
| 2022-03-31 | 30.65K shares 10-Q · filed 2022-05-06 | 60.71K shares derived: sum of 2 quarters · filed 2022-05-06 | 119.61K shares derived: sum of 3 quarters · filed 2022-05-06 | 181.34K shares derived: sum of 4 quarters · filed 2022-05-06 |
| 2021-12-31 | 30.06K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | 88.96K shares derived: sum of 2 quarters · filed 2022-03-15 | 150.69K shares derived: sum of 3 quarters · filed 2022-03-15 | 356.88K shares 10-K · filed 2022-03-15 |
| 2021-09-30 | 58.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 120.63K shares derived: sum of 2 quarters · filed 2021-11-09 | 326.82K shares 10-Q · filed 2021-11-09 | 378.05K shares derived: sum of 4 quarters · filed 2021-11-09 |
| 2021-06-30 | 61.73K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | 267.92K shares 10-Q · filed 2021-08-06 | 319.15K shares derived: sum of 3 quarters · filed 2021-08-06 | 494.03K shares derived: sum of 4 quarters · filed 2021-08-06 |
| 2021-03-31 | 206.19K shares 10-Q · filed 2021-05-11 | 257.42K shares derived: sum of 2 quarters · filed 2021-05-11 | 432.30K shares derived: sum of 3 quarters · filed 2021-05-11 | 626.08K shares derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-12-31 | 51.23K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | 226.11K shares derived: sum of 2 quarters · filed 2021-03-05 | 419.89K shares derived: sum of 3 quarters · filed 2021-03-05 | 420.68K shares 10-K · filed 2021-03-05 |
| 2020-09-30 | 174.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 368.66K shares derived: sum of 2 quarters · filed 2020-11-05 | 369.45K shares 10-Q · filed 2020-11-05 | |
| 2020-06-30 | 193.77K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | 194.56K shares 10-Q · filed 2020-08-14 | ||
| 2020-03-31 | 793.00 shares 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |